Acura Pharmaceuticals last week announced that it has been awarded a $300,000 grant by the National Institute On Drug Abuse of the National Institutes of Health to fund Phase I development of Acura's new, early stage Limitx abuse deterrent technology.
Among patients with hypertension at high risk of cardiovascular disease, a program where patients measured their blood pressure and adjusted their antihypertensive medication accordingly resulted in lower systolic blood pressure at 12 months compared with patients who received usual care, according to a study in the Aug. 27 issue of JAMA.
The asthma treatment market value will grow from approximately $15.9 billion in 2013 across eight major countries — the United States, United Kingdom, France, Germany, Spain, Italy, Japan and Australia — to $23.1 billion by 2023, according to research and consulting firm GlobalData.
More than 55% of people suffer from swallowing difficulties when taking tablets or capsules, which is likely to inhibit compliance, according to an international survey conducted by Spiegel Institute Mannheim on behalf of Hermes Pharma.
UCB on Monday announced that the Food and Drug Administration has approved a supplemental new drug application for Vimpat (lacosamide) C-V as monotherapy in the treatment of partial-onset seizures in patients with epilepsy ages 17 years and older.
Pfizer last week announced that the Food and Drug Administration has granted fast track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090).
Rx Safes, manufacturer of fingerprint recognition home prescription lockboxes, on Thursday announced that it is waging a new war on drugs to reduce prescription drug abuse, backed by a national media campaign.